drugset / Trial / NCT02021097

Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception

NCT02021097

Phase 3 Unknown 1008 enrolled Regenex Pharmaceutical, China
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the contraceptive efficacy and safety of an oral contraceptive containing a combination of LNG 100mcg/EE 20mcg compared to LNG 150mcg/EE 30 mcg.

Timeline

Start
2012-02
Primary completion
2015-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule 100 ug Oral
Subject Levonorgestrel Small molecule 150 ug Oral
Subject ethinyl estradiol Small molecule 20 ug Oral
Subject ethinyl estradiol Small molecule 30 ug Oral

Indications

No indication recorded.